Abstract
Study objective: It is important for researchers interested in trials using the exception from informed consent to understand the views and experiences of enrolled individuals. Previous studies have shown that patient and surrogate attitudes are generally positive. These studies were small and did not include pediatric patients, and interviews were often conducted long after trial enrollment. This study sought to explore attitudes toward exception from informed consent in a larger sample and more contemporaneous setting. Methods: A 10-item paper-and-pencil survey was integrated into the Established Status Epilepticus Treatment Trial, a randomized trial of 3 treatments for benzodiazepine-refractory status epilepticus in pediatric and adult patients. Primary domains included attitudes toward trial enrollment, exception from informed consent, and community consultation. Simple descriptive statistics, χ2, and Fisher's exact tests were conducted. Results: Of 317 patients and surrogates, 90% agreed with or were neutral about the statement “I am glad that I/my family member was included in the Established Status Epilepticus Treatment Trial research study,” whereas 10% disagreed. Twenty-seven percent disagreed with enrollment in the study without prospective consent. Black participants were more likely than white, other race, and unknown-race participants to disagree with enrollment without prospective consent (36% versus 23%, 14%, and 14%, respectively). Participants indicated that patients (81%), their families (65%), and those at risk for seizures (51%) were most important to include in community consultation. Conclusion: This study aimed to explore attitudes toward exception from informed consent enrollment among participants at all sites in a large, multicenter exception from informed consent trial. General acceptance of trial enrollment was high; acceptance of exception from informed consent specifically was somewhat lower, especially among black participants. Our findings provide further support for targeted community consultation focusing on individuals with connections to the disease under study. Future research should focus on communication in the postenrollment period, especially with individuals who may have concerns about exception from informed consent.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 343-349 |
| Number of pages | 7 |
| Journal | Annals of Emergency Medicine |
| Volume | 76 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2020 |
Bibliographical note
Funding Information:Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). This project was part of the Established Status Epilepticus Treatment Trial, which was funded by the National Institutes of Health (NIH) and NINDS (project 1U01NS088034-01). Dr. Dickert reports receiving research support from National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences, National Institute of Child Health and Human Development, and Patient Centered Outcomes Research Institute. Dr. Silbergleit reports that the institution where his research is conducted receives NIH grants. Dr. Wright reports receiving research support from NIH, the Centers for Disease Control and Prevention, Department of Defense?Tracks TBI, Marcus Foundation?VICTAS trial, and National Highway Traffic Safety Administration Crash Injury Research, as well as participating on scientific advisory boards for Astrocyte Pharma, SENSE Diagnostics, and ISCHEMIX.
Funding Information:
Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org ). This project was part of the Established Status Epilepticus Treatment Trial, which was funded by the National Institutes of Health (NIH) and NINDS (project 1U01NS088034-01 ). Dr. Dickert reports receiving research support from National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences , National Institute of Child Health and Human Development , and Patient Centered Outcomes Research Institute . Dr. Silbergleit reports that the institution where his research is conducted receives NIH grants. Dr. Wright reports receiving research support from NIH, the Centers for Disease Control and Prevention, Department of Defense–Tracks TBI, Marcus Foundation–VICTAS trial, and National Highway Traffic Safety Administration Crash Injury Research, as well as participating on scientific advisory boards for Astrocyte Pharma, SENSE Diagnostics, and ISCHEMIX.
Publisher Copyright:
© 2020 American College of Emergency Physicians